SEC Form 4 · accession 0001104659-15-086780
Axsome Therapeutics, Inc. · AXSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Randall Kaye
Officer — Chief Medical Officer
Period of report
Dec 23, 2015
Accepted (ET)
Dec 24, 2015 · 1:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001579428
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 23, 2015 | P | 1,000 | $9.026 | A | 6,022 | I | By children |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.99 to $9.15, inclusive. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth above.